Innovations in care
Advanced heart failure
Inova Reinsch Pierce Cardiomyopathy Program offers multidisciplinary expertise
New therapies and advances in genetic testing have changed the landscape of cardiomyopathy care, and specialized expertise can mean more healthy years for patients. The Inova Reinsch Pierce Cardiomyopathy Program provides cardiovascular care to patients with all forms of cardiomyopathy.
Leading innovation in management of potential LVAD complications
Findings from a two-year follow-up study, lead by Inova experts, support the long term feasibility of apixaban anticoagulation in patients with a left ventricular assist device (LVAD) and underscores the need for larger randomized trials.
Advanced lung disease
Multimodal approach is key to curing CTEPH
Although a history of venous thromboembolism (VTE) may predispose a patient to development of chronic thromboembolic pulmonary hypertension (CTEPH), up to 50% of patients with CTEPH have no prior diagnosis of VTE, making an accurate diagnosis challenging. Inova’s Pulmonary Hypertension Program offers patients a comprehensive evaluation through its multidisciplinary CTEPH service.
A second chance at adventure after lung transplant
A lung transplant enabled Jenny Simpson to enjoy six-and-a-half more years oxygen-free. Her daughter, Missy Hertless, credits the care team at Inova with giving Jenny the support, guidance and encouragement she needed, both before and after transplant.
A second chance at adventure after lung transplant
A lung transplant enabled Jenny Simpson to enjoy six-and-a-half more years oxygen-free. Her daughter, Missy Hertless, credits the care team at Inova with giving Jenny the support, guidance and encouragement she needed, both before and after transplant.
Cardiac and respiratory failure
Call early, call often: When is the right time to transfer a patient in cardiogenic shock?
Shashank S. Sinha, MD, led development of the American College of Cardiology’s concise clinical guidance for cardiogenic shock. The guidance lays out state-of-the-art shock management guidance with practical concepts providers can implement and incorporate in their day-to-day practice.
Call early, call often: When is the right time to transfer a patient in cardiogenic shock
Shashank S. Sinha, MD, led development of the American College of Cardiology’s concise clinical guidance for cardiogenic shock. The guidance lays out state-of-the-art shock management guidance with practical concepts providers can implement and incorporate in their day-to-day practice.
Cardiac surgery
Dedicated expertise leads to outstanding outcomes for Type A aortic dissection
Nationwide, the patient survival rate for surgical repair of a Type A aortic dissection is 50% to 60%. Yet at Inova Schar Heart and Vascular at Fairfax Hospital, approximately 90% of patients survive. What accounts for these drastically different results?
Inova among the first to offer ShortCut technology for valve-in-valve TAVR redos
In 2025, Inova’s expert structural heart and valve disease team began using Pi-Cardia’s ShortCut™ catheter, the only FDA-approved device for leaflet modification in valve-in-valve transcatheter aortic valve replacement (TAVR), also known as a “redo” TAVR. Inova is among the first health systems in the nation to use this technology, which is the only device that has been approved for this application.
Cora is off to the races, thanks to Inova’s comprehensive congenital heart care
After a fetal ultrasound detected the heart difference, Cora’s parents came to Inova Children’s Fetal Care Center for counseling. The team determined that Cora would need staged surgeries to rebuild her heart and ensure it functions with only one pumping chamber.
Cora is off to the races, thanks to Inova’s comprehensive congenital heart care
After a fetal ultrasound detected the heart difference, Cora’s parents came to Inova Children’s Fetal Care Center for counseling. The team determined that Cora would need staged surgeries to rebuild her heart and ensure it functions with only one pumping chamber.
Clinical research
The comprehensive clinical research enterprise at Inova Schar Heart and Vascular
With the support of Inova’s leadership, Inova Schar Heart and Vascular has built a comprehensive clinical research enterprise that spans many dimensions of cardiology and offers a menu of trials that rivals the nation’s elite heart centers.
Top Inova Schar Heart and Vascular research papers for 2025
Inova is committed to academic excellence and innovation in clinical research, education and mentorship. Publishing in peer-reviewed journals advances knowledge, translates evidence into best practices and is critical to providing outstanding care for our patients.
Electrophysiology
Interventional cardiology
Medicare expands coverage for renal denervation treatment of resistant hypertension
The Centers for Medicare & Medicaid Services recently finalized its national coverage analysis for renal denervation to cover both radiofrequency and ultrasound renal denervation. Inova Schar Heart and Vascular offers both procedures to treat resistant hypertension.
Multimodal approach is key to curing CTEPH
Although a history of VTE may predispose a patient to development of CTEPH, up to 50% of patients with CTEPH have no prior diagnosis of VTE, making an accurate diagnosis challenging. Inova’s Pulmonary Hypertension Program offers patients a comprehensive evaluation through its multidisciplinary CTEPH service.
Rampart system keeps team members safe from radiation overexposure
In 2025, Inova implemented state-of-the-art leadless Rampart radiation protection systems. This cutting-edge technology is transforming Inova’s clinical safety protocols in high-radiation areas like cardiac catheterization labs, electrophysiology labs and interventional radiology suites.
Structural heart
Inova among the first to offer ShortCut™ technology for valve-in-valve TAVR redos
In 2025, Inova’s expert structural heart and valve disease team began using Pi-Cardia’s ShortCut catheter, the only FDA-approved device for leaflet modification in valve-in-valve TAVR, also known as a “redo” TAVR. Inova is among the first health systems in the nation to use this technology, which is the only device that has been approved for this application.
Inova among the first to offer ShortCut™ technology for valve-in-valve TAVR redos
In 2025, Inova’s expert structural heart and valve disease team began using Pi-Cardia’s ShortCut catheter, the only FDA-approved device for leaflet modification in valve-in-valve TAVR, also known as a “redo” TAVR. Inova is among the first health systems in the nation to use this technology, which is the only device that has been approved for this application.
Specialized services
Inova among the first to offer ShortCut™ technology for valve-in-valve TAVR redos
In 2025, Inova’s expert structural heart and valve disease team began using Pi-Cardia’s ShortCut catheter, the only FDA-approved device for leaflet modification in valve-in-valve TAVR, also known as a “redo” TAVR. Inova is among the first health systems in the nation to use this technology, which is the only device that has been approved for this application.
Cardiogenetics helps refine management for patients and families
Cardiogenetics can significantly improve treatment and management for patients with cardiovascular conditions linked to genetic factors. For more than 10 years, the Inova Cardiovascular Genomics Center has provided comprehensive cardiovascular genetic testing and counseling, expanding access to this crucial information.
Inova Reinsch Pierce Cardiomyopathy Program offers multidisciplinary expertise
New therapies and advances in genetic testing have changed the landscape of cardiomyopathy care, and specialized expertise can mean more healthy years for patients. The Inova Reinsch Pierce Cardiomyopathy Program provides cardiovascular care to patients with all forms of cardiomyopathy.
Medicare expands coverage for renal denervation treatment of resistant hypertension
The Centers for Medicare & Medicaid Services recently finalized its national coverage analysis for renal denervation to cover both radiofrequency and ultrasound renal denervation. Inova Schar Heart and Vascular offers both procedures to treat resistant hypertension.
Vascular medicine and surgery
A multidisciplinary approach leads to healing and limb preservation for George
In an effort to avoid amputation due to diabetic neuropathy, Inova’s vascular surgery team coordinated closely with a community-based podiatrist and the Inova Wound Healing Centers to revascularize blood flow to George Harte's foot and toe, enabling his persistent foot ulcers to heal.
A multidisciplinary approach leads to healing and limb preservation for George
In an effort to avoid amputation due to diabetic neuropathy, Inova’s vascular surgery team coordinated closely with a community-based podiatrist and the Inova Wound Healing Centers to revascularize blood flow to George Harte's foot and toe, enabling his persistent foot ulcers to heal.
Patient transfers
One call 24/7 703-776-8000
Direct admission ▪ Transfer ▪ Specialized transport ▪ Cardiogenic shock transfers